TTC Oncology
TTC Oncology developed TTC-352, a small molecule to fight breast cancer
Overview
Raised: $143,230
Rolling Commitments ($USD)
04/30/2023
$281
76
2015
Healthcare & Pharmaceuticals
Biotech
B2B/B2C
Medium
High
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$0 |
$0 |
COGS |
$0 |
$0 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-99,617 |
$-1,207,239 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$117,558 |
$87,628 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$486,339 |
$485,956 |
Short-Term Debt |
$0 |
$0 |
Long-Term Debt |
$408,446 |
$408,446 |
Total Liabilities |
$408,446 |
$408,446 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual